Zydus Cadila gets tentative FDA nod for Ribavirin

 The drug, falling in the anti-infectives segment, is used as an anti-viral therapy, and will go off patent in December 2005, the company announced in a release issued to the BSE today.

 "The abbreviated new drug application (ANDA) approval is an addition to the 7 ANDA approvals the company has received earlier," the release added.